-
Mashup Score: 0
The FDA has granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen [now part of Pfizer]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication.
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Stakeholders Embrace Home Cancer Care - 1 month(s) ago
A pilot program begun during the COVID-19 pandemic to allow New Jersey residents with cancer to receive chemotherapy infusions at home was so successful that it has become standard practice.
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1HHS Releases Succinct Cybersecurity Insurance Guides - 1 month(s) ago
The Department of Health and Human Services released two one-page guides in December about considerations that healthcare leaders should weigh when purchasing cybersecurity insurance.
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Cases of Rare, Fatal Cancer Linked to Celiac Disease Increasing - 1 month(s) ago
The incidence of enteropathy-associated T-cell lymphoma—a rare and aggressive T-cell, non-Hodgkin lymphoma—is rising, according to new data.
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Empathy Promotes Psychological Well-Being in Breast Cancer Patients - 2 month(s) ago
Clinicians who show more empathy promote better psychological health among breast cancer patients, according to a Rutgers study examining how oncology doctors facilitate psychological well-being.
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Acupuncture and massage are beneficial to patients with advanced cancer pain, according to the findings of the IMPACT trial, with no statistically significant difference between the two therapies.
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Grants Accelerated Approval to Brukinsa for Relapsed or Refractory Follicular Lymphoma - 2 month(s) ago
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) with obinutuzumab (Gazyva, Genentech) for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Approves Opdivo Combination for Unresectable or Metastatic Urothelial Carcinoma - 2 month(s) ago
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The FDA approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Mailed FIT Yields Impressive CRC Screening Participation Rates in Health-System Study - 2 month(s) ago
A more proactive approach to CRC screening using FIT resulted in high participation and detection rates across a large health system, according to new data.
Source: www.clinicaloncology.comCategories: General Medicine News, Onc News and JournalsTweet
The FDA has granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen [now part of Pfizer]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. https://t.co/ba7FJbiqz4